Organigram Global Inc.
$1.51
▲
2.99%
2026-04-21 08:36:00
www.organigram.ca
NMS: OGI
Explore Organigram Global Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$274.04 M
Current Price
$1.51
52W High / Low
$3.09 / $1.37
Stock P/E
15.08
Book Value
$1.97
Dividend Yield
—
ROCE
-3.51%
ROE
4.64%
Face Value
—
EPS
$0.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,137
Beta
1.87
Debt / Equity
1.99
Current Ratio
2.73
Quick Ratio
1.28
Forward P/E
77.78
Price / Sales
0.69
Enterprise Value
$244.28 M
EV / EBITDA
44.96
EV / Revenue
0.87
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Neurocrine Biosciences, Inc. | $130.77 | 28.05 | $13.18 B | — | 16.37% | 16.38% | $160.18 / $98.95 | $32.5 |
| 2. | InMed Pharmaceuticals Inc. | $0.72 | — | $2.4 M | — | -57.63% | -97.2% | $7.98 / $0.57 | $3.42 |
| 3. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
| 4. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 5. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 6. | Tilray Brands, Inc. | $7.15 | — | $833.32 M | — | -6.01% | -63.16% | $23.2 / $3.51 | $14.89 |
| 7. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 63.54 M | 80.06 M | 70.79 M | 65.6 M | 42.73 M | — |
| Operating Profit | -3.42 M | 1.19 M | -2.1 M | -7.58 M | -6.8 M | — |
| Net Profit | 19.97 M | -37.96 M | -6.29 M | 42.46 M | -22.96 M | — |
| EPS in Rs | 0.15 | -0.28 | -0.05 | 0.31 | -0.17 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 259.18 M | 159.84 M | 145.81 M | 79.16 M |
| Operating Profit | -15.3 M | -34.76 M | -38.75 M | -72.84 M |
| Net Profit | -24.76 M | -45.44 M | -14.28 M | -130.7 M |
| EPS in Rs | -0.18 | -0.33 | -0.1 | -0.96 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 562.21 M | 407.86 M | 577.11 M | 554.02 M |
| Total Liabilities | 213.08 M | 101.87 M | 69.05 M | 74.21 M |
| Equity | 349.13 M | 305.99 M | 508.06 M | 479.81 M |
| Current Assets | 284.9 M | 262.22 M | 221.62 M | 260.62 M |
| Current Liabilities | 126.16 M | 53.32 M | 55.28 M | 26.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -7.59 M | 3.87 M | -36.21 M | -28.59 M |
| Investing CF | -81.07 M | -30.8 M | 44.03 M | -115.11 M |
| Financing CF | 39.33 M | 107.78 M | 5.33 M | 174.46 M |
| Free CF | -24.64 M | -1.47 M | -84.99 M | -40.88 M |
| Capex | -17.05 M | -5.34 M | -48.78 M | -12.29 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 62.15% | — | 84.19% | — |
| Earnings Growth % | 45.51% | — | 89.07% | — |
| Profit Margin % | -9.55% | -28.43% | -9.8% | -165.11% |
| Operating Margin % | -5.9% | -21.74% | -26.58% | -92.01% |
| Gross Margin % | 34.81% | 29.73% | 21.65% | -35.87% |
| EBITDA Margin % | 1.03% | -14.19% | 7.52% | -122.17% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-07 | 1:0.25 |